Janus Henderson Group PLC Has $347.65 Million Position in Novartis AG $NVS

Janus Henderson Group PLC grew its holdings in Novartis AG (NYSE:NVS) by 1.9% in the first quarter, Holdings Channel.com reports. The firm owned 2,275,938 shares of the company’s stock after purchasing an additional 41,520 shares during the period. Janus Henderson Group PLC’s holdings in Novartis were worth $347,649,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. J.W. Cole Advisors Inc. grew its stake in Novartis by 0.6% during the 4th quarter. J.W. Cole Advisors Inc. now owns 10,577 shares of the company’s stock valued at $1,348,000 after acquiring an additional 64 shares in the last quarter. Roundview Capital LLC lifted its position in shares of Novartis by 2.5% in the fourth quarter. Roundview Capital LLC now owns 2,711 shares of the company’s stock worth $374,000 after purchasing an additional 66 shares in the last quarter. IMA Advisory Services Inc. lifted its position in shares of Novartis by 10.9% in the fourth quarter. IMA Advisory Services Inc. now owns 710 shares of the company’s stock worth $98,000 after purchasing an additional 70 shares in the last quarter. Abundance Wealth Counselors boosted its holdings in shares of Novartis by 0.4% during the fourth quarter. Abundance Wealth Counselors now owns 16,927 shares of the company’s stock worth $2,334,000 after purchasing an additional 73 shares during the period. Finally, Atlantic Edge Private Wealth Management LLC boosted its holdings in shares of Novartis by 3.5% during the fourth quarter. Atlantic Edge Private Wealth Management LLC now owns 2,230 shares of the company’s stock worth $307,000 after purchasing an additional 75 shares during the period. Institutional investors and hedge funds own 13.12% of the company’s stock.

Novartis Stock Performance

Shares of NVS stock opened at $158.45 on Friday. Novartis AG has a fifty-two week low of $112.34 and a fifty-two week high of $170.46. The stock’s 50-day moving average is $152.58 and its two-hundred day moving average is $152.70. The company has a debt-to-equity ratio of 0.89, a current ratio of 0.86 and a quick ratio of 0.67. The firm has a market cap of $302.35 billion, a P/E ratio of 23.90, a PEG ratio of 2.73 and a beta of 0.45.

Novartis (NYSE:NVS) last announced its quarterly earnings results on Tuesday, June 30th. The company reported $2.41 earnings per share (EPS) for the quarter. The business had revenue of $14.95 billion during the quarter. Novartis had a return on equity of 38.56% and a net margin of 23.29%. Analysts predict that Novartis AG will post 8.82 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on NVS shares. Citigroup reiterated a “buy” rating on shares of Novartis in a research note on Wednesday, July 22nd. Weiss Ratings reissued a “buy (b)” rating on shares of Novartis in a research note on Friday, July 24th. Seven analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $141.20.

Novartis Company Profile

Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide.

The company’s activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies.